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Abstract
Some hormone-independent breast cancers lack func-
tional estrogen receptors (ERs) and show evidence of
a more aggressive metastatic phenotype. A protective
role of the ER has also been suggested in hormone-
resistant breast cancer progression. In this study, we
have investigated the effect of the ectopic expression
of human ERA on the bone-metastatic potential of
highly metastatic ERA-negative human breast cancer
MDA-MB-231 and MDA-MB-435-F-L cell lines in an ex-
perimental model of bone metastasis in nude mice.
ERA overexpression had no effect on the growth of
both cell lines but reduced the expression of integrin
AvB3 and the receptor activator of NF-KB, which are
known to promote bone metastasis. A significant
reduction in the incidence of osteolytic bone metas-
tasis was observed by X-ray imaging of the legs and
arms of mice inoculated with ERA-expressing clones
of MDA-MB-231 cells in comparison to controls. Ec-
topic expression of ERA in MDA-MB-435-F-L cells
also reduced their widespread skeletal metastasis to
the legs, arms, spine, and mandible, as detected by
whole-mouse enhanced green fluorescent protein
imaging. Our study indicates for the first time that
stable reintroduction of functional ERA in ERA-negative
human breast cancer cells can inhibit their aggres-
sive bone-metastatic potential in an experimental bone
metastasis model.
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Introduction
In the United States, breast cancer is the most common
malignancy and second leading cause of cancer-related
deaths in women [1]. Metastasis to distant organs, espe-
cially to the bone and lungs, is the leading cause of mor-
bidity and death in breast cancer patients. Estrogen, which
exerts its effects by binding to estrogen receptor a (ERa;
expressed in about 70% of breast cancers) and ERb, has
been implicated in the malignant progression of breast
cancer [2]. As tumor progresses, ERa-positive tumors may
lose ERa expression and become estrogen-independent
with increasing risk of metastasis [3]. These invasive and
metastatic ERa-negative tumors respond poorly to endocrine
therapy, chemotherapy, and radiation treatment [4,5]. There-
fore, the probability of death is much greater for patients
with ERa-negative breast tumors than for patients with ERa-
positive breast tumors [6]. However, the presence of ERa in
tumors has been related to a favorable response to endocrine
therapy and improves overall survival [7]. In a recent report,
epigenetically reactivated ERa in ER-negative breast cancer
cells restored their sensitivity to endocrine therapy [8]. In ad-
vance breast cancer, bone metastasis is prevalent in > 80%
of patients (http://www.cancer.org/cancerinfo). In addition to
debilitating osteolysis, tumor cells in the bone marrow corre-
lated with recurrence and poor patient survival [9]. A clinical
study showed that patients with ER+/progesterone (PR+)
tumors had a lower frequency of disseminated tumor cells in
the bone marrow, compared to patients with ER/PR tumors
[10]. In this study, we have stably transfected two highly meta-
static ERa-negative human breast cancer cell lines, MDA-MB-
435-F-L and MDA-MB-231, with ERa and have evaluated
their bone-metastatic potential in comparison to control cells
in an intracardiac injection model of skeletal metastasis in
nude mice. Our results showed for the first time that these
ERa-negative cell lines expressing functional ERa signifi-
cantly inhibited both tumor cell homing to the skeleton and
osteolysis, indicating that restoration of ERa might be a poten-
tial therapeutic approach for the inhibition of bone metastasis in
hormone-independent breast cancer.
Materials and Methods
Animals and Cell Lines
Four- to 5-week-old female athymic nude mice (obtained
from Harlan Sprague Dawley, Inc., Indianapolis, IN) were used
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for in vivo animal experiments. The animals were housed
under specific pathogen-free conditions. All animal protocols
were approved and monitored by the institutional animal care
and use committee.
MDA-MB-435-F-L cells, which are highly invasive and
metastatic variants of human breast carcinoma MDA-MB-
435 cells, were isolated in our laboratory [11]. The human
breast cancer cell line MDA-MB-231 was originally obtained
from the American Type Culture Collection (Manassas, VA).
These cell lines were cultured in McCoy’s 5A medium supple-
mented with pyruvate, vitamins, amino acids, antibiotics, and
10% fetal bovine serum, as previously described [12]. To
detect their potential for early metastasis to the bone, we
stably transfected the enhanced green fluorescent protein
(EGFP) expression plasmid pEGFP-N1 (Clontech Labora-
tories, Inc., Mountain View, CA) into these cell lines and sorted
out a pool of EGFP-expressing cells for further studies.
Transfection and Expression of ERa in Human Breast
Cancer Cell Lines
MDA-MB-231 and MDA-MB-435-F-L cells expressing
EGFP were transfected with a retroviral ERa expression
vector, ERa/pBabe-Puro, or pBabe-puro as control. Stable
transfectants resistant to puromycin treatment (3.0 mg/ml)
were isolated by limiting dilution clones. Puromycin-resistant
control clones were pooled as a control cell line. To confirm
whether ectopic ERa is functional, both MDA-MB-231 and
MDA-MB-435-F-L control cells and their respective ERa
clones were transiently cotransfected with an estrogen-
responsive promoter luciferase plasmid (thymidine kinase–
ERE–Luciferase) and a b-galactosidase (b-gal) expression
plasmid. At 3 hours after transfection, cells were treated
with or without 17b-estradiol (E2; 10
7 M) for 20 hours. Lucif-
erase activity normalized with b-gal activity in cell lysates
was then determined as described previously [13].
Cell Proliferation Assay
MDA-MB-231 and MDA-MB-435-F-L control cells and
their respective ERa clones were plated in a 96-well plate
at 2000 cells/well, and 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay was used to ob-
tain the relative cell number after 5 days of incubation, as
described previously [14].
Western Blot Analysis
The cell lysates of both control cells and ERa clones of
MDA-MB-231 and MDA-MB-435-F-L cells were used in
Western blot analysis, as described previously [15]. Anti-
body to integrin b3 was obtained from Cell Signaling Tech-
nology (Beverly, MA), and antibodies to ERa, integrin av, and
the receptor activator of NF-nB (RANK) were obtained from
Santa Cruz Biotechnology (Santa Cruz, CA).
Experimental In Vivo Bone and Lung Metastasis Assay
An intracardiac injection model for experimental bone
metastasis was used for this study, as previously described
[16]. Briefly, MDA-MB-231 and MDA-MB-435-F-L control
cells and their respective ERa clones were harvested from
subconfluent exponentially growing cultures. The cells were
injected into the left cardiac ventricle of anesthesized fe-
male nude mice (5 weeks old) with a 27-gauge needle at-
tached to a 1-ml syringe using a micromanipulator. Each
mouse was injected with 105 cells in 0.1 ml of phosphate-
buffered saline, and successful injections were indicated
by the pumping of red blood into the syringe. Development
of bone metastasis induced by EGFP-expressing MDA-
MB-435-F-L cells was monitored at regular intervals by
whole-animal imaging for green fluorescence to detect
EGFP-expressing tumor cells growing in the legs, arms,
spine, and mandible bones, using a Nikon SMZ1500 (Nikon,
Tokyo, Japan) fluorescence stereoscope attached to a
CoolSNAP CCD camera (Photometrics, Tucson, AZ). EGFP
expression was mostly lost in MDA-MB-231 cells after trans-
fection with pBabe-puro or ERa/pBabe-puro. Therefore,
X-ray radiographs taken with Faxitron were used for the
detection of any bone lesion in mice injected with MDA-
MB-231 cells. After the termination of experiment at about
4 weeks, whole lungs were excised, and EGFP-expressing
metastatic cancer cell colonies were visually observed and
counted under an inverted fluorescence microscope. Bone
tissues were fixed in 10% neutral-buffered formalin (Fisher
Scientific, Houston, TX) for 24 hours at room temperature,
decalcified in 10% EDTA, and embedded in paraffin. Sec-
tions were stained with hematoxylin, eosin, orange G, and
phloxine, and the presence of metastatic tumors and bone
osteolysis in the femora and tibiae was examined above and
below a growth plate under a microscope.
Results and Discussion
The bone is the most common site of metastases in patients
with breast carcinoma. Patients with ER-positive bone me-
tastases usually have a prognosis better than that of patients
with ER-negative bone metastases [17], suggesting a pro-
tective role of ER in tumor progression associated with
bone metastasis. ER-positive tumors in breast cancer
patients are more differentiated and have lower metastatic
potential, in comparison to ER-negative tumors [18]. In this
study, we examined whether stable reintroduction of func-
tional human ERa in ERa-negative human breast cancer
cells could alter their bone-metastatic potential in an ex-
perimental bone metastasis model. We used two bone-
metastatic ERa-negative human breast cancer cell lines for
the stable transfection of ERa, MDA-MB-231 cells (which are
highly osteolytic) [19], and MDA-MB-435-F-L cells (which
are highly invasive and capable of widespread skeletal
metastasis) [11] in animal models. We isolated and charac-
terized the ERa clones of each cell line after stable transfec-
tion with an expression vector for wild-type human ERa. The
expression of ERa was detected by Western blot analysis
in MDA-MB-231 ERa clones 11 and 15 and in MDA-MB-435-
F-L ERa clones 3 and 6, even though it was lower than that
in ERa-positive breast cancer MCF-7 cells (Figure 1A). ERa
was undetectable in control vector–transfected cells (Fig-
ure 1A). The estrogen sensitivity of the ERa clones of both
cell lines was confirmed with E2-mediated induction of an
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estrogen-responsive promoter activity reported by luciferase
activity and compared also with the ERa-positive human
breast cancer MCF-7 cell line. Both ERa-expressing clones
ofMDA-MB-231 cells (Figure 1B) andMDA-MB-435-F-L cells
(Figure 1C) showed high levels of promoter activity, which
was further stimulated after treatment with E2, suggesting
that ectopic ERa is functional.
Although the expression of ERa greatly increased
estrogen-responsive promoter activity, it showed a limited
effect on the growth of both cell lines on plastic (Figure 1D).
Previous studies have shown that the expression of ectopic
ERa in ERa-negative human mammary epithelial cells led
to growth inhibition through treatment with E2 at concen-
trations between 1010 and 107 M [20–22]. However, we
only observed a moderate growth inhibition of some ERa-
transfected clones through treatment with E2 within the
same concentration range (data not shown). This discrep-
ancy is likely due, in part, to the fact that ectopic ERa levels
in our clones appear to be lower than those in published
studies [20–22] when the ERa level in MCF-7 cell was used
as standard.
To investigate the bone-metastatic potential of ERa-
expressing clones compared to that of parental cells in both
cell lines, we used an intracardiac injection model of ex-
perimental metastasis. Female nude mice were inoculated
with MDA-MB-231 and MDA-MB-435-F-L control cells or
their respective ERa clones through the left ventricle of the
heart. Bone metastasis induced by MDA-MB-435-F-L control
cells and ERa clones (clones 3 and 6) was monitored by
whole-mouse EGFP imaging, as described earlier [14]. Be-
cause MDA-MB-231 transfectants did not retain EGFP ex-
pression and the cell line was known to induce osteolytic
bone metastasis, whole-mouse X-ray imaging was used to
detect osteolytic bone metastasis induced by MDA-MB-231
control and ERa clones. Whole-mouse EGFP imaging on
week 4 after inoculation revealed that the expression of ERa
Figure 1. Ectopic expression of functional ERa in human breast cancer cells. (A) MDA-MB-231 and MDA-MB-435-F-L cells were transfected with either a retroviral
ERa expression vector or an empty vector, which carried a puromycin-resistant gene. Puromycin-resistant clones were selected, and the expression of ERa was
determined by Western blot analysis with cell lysates from empty vector – transfected controls (Con) and ERa clones of the MDA-MB-231 and MDA-MB-435-F-L
cell lines. In a separate Western blot analysis, the ERa level in MDA-MB-231 Cl.15 was compared with that in ERa-positive human breast cancer MCF-7 cells.
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) levels were measured in cell lysates to show equal sample loading. (B and C) To confirm the expression of
a functional ERa in ERa clones of MDA-MB-231 (B) and MDA-MB-435-F-L (C) cells, the control cells, ERa clones and MCF-7 cells, were transiently cotransfected
with an estrogen-responsive promoter luciferase plasmid (ERE– thymidine kinase–Luciferase) and a -gal expression plasmid. Cells were treated with 107 M E2.
Luciferase and -gal activities in cell lysates were determined. Luciferase activity normalized with -gal activity is presented as the mean ± SEM for each treatment
from triplicate transfections. *Significant difference (P < .05) from the corresponding control without E2 treatment, by Student’s t test. (D) To determine the effect of
ERa expression on the growth of MDA-MB-231 and MDA-MB-435-F-L cells, the controls and two ERa clones were plated in a 96-well plate, and MTT assay was
performed to obtain the relative cell number. Each point represents the mean ± SEM from four wells. The means of the three cells at each time point were not
significantly different by ANOVA.
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markedly reduced the widespread skeletal metastasis in-
cidence induced by MDA-MB-435-F-L cells (Table 1A). The
incidence of metastasis in the femur/tibia, spine, and man-
dible of control cell– inoculated mice was 75%, whereas in
ERa clone–inoculated mice, it ranged between 0% and 33%.
The difference in metastasis incidence between the femur/
tibia and the mandible was statistically significant by Fisher’s
exact probability test. Similarly, the incidence of osteolytic
bone metastasis as detected by X-ray imaging in the legs
and arms of mice inoculated with ERa clones of MDA-MB-
231 cells for 3 weeks was significantly reduced in compar-
ison to that of control mice (P < .05) (Table 1B and Figure 2A).
It was 80% and 40%, respectively, in the legs and arms
of control cell– inoculated mice, whereas in ERa clone–
inoculated mice, it ranged between 0% and 10%. We also
examined the presence of tumor cells in stained histologic
sections of the femur and tibia of mice inoculated with both
control cell lines or their ERa-expressing clones. Represen-
tative bone histology pictures are shown in Figure 2, B andC.
The incidences of bone metastasis in the femora and tibiae
obtained by histology examination were identical to those
obtained by EGFP imaging or X-ray imaging, as shown in
Table 1. In these stained bone sections, it is evident that
the growth of metastatic tumors was associated with osteol-
ysis, as reflected by the loss of trabecular bones in control
cell– inoculated mice (Figure 2, B and C). Because the
majority of mice inoculated with ERa clones did not have
tumor cells in the tibiae and femora, it is not clear whether
ERa expression in the two breast cancer cell lines can also
inhibit osteolysis. Thus, our studies indicate that the inhibi-
tion of skeletal metastasis by the expression of ERa in ERa-
negative breast cancer cells appears due to the inhibition
of cancer cell homing in the bone marrow. At present, it is
not clear whether ERa cells failed to invade the bone marrow
or whether they did not proliferate in the bone marrow.
Ectopic expression of ERa in MDA-MB-231 cells has been
previously shown to inhibit its invasive potential in vitro and
to reduce the number and burden of lung metastases when
the cells were inoculated through the tail vein of nude mice
[22]. Thus, it is likely that the attenuated invasive potential
after ERa expression contributed significantly to the loss
of bone-metastatic potential in MDA-MB-231 and MDA-MB-
435-F-L cells.
Integrins, which are cell surface receptors involved in cell
adhesion, migration, invasion, and survival, have been impli-
cated in the malignant progression of cancer [23]. Several
studies indicated a role for integrin avb3 in the promotion
of both spontaneous and experimental metastases to the
bone in animal models [14,24–26]. In a clinical study, integrin
avb3 was found to be overexpressed in metastatic breast
cancer cells within the bone, compared to primary breast
adenocarcinoma [27]. The level of integrin avb3 was found
to be significantly lower in tumors initiated from an ERa-
transfected human endometrial cancer cell line than in tu-
mors originated from an ERa-negative parental cell [28].
Because systemic treatment with an antagonist of integrin
avb3 has been shown to inhibit bone metastasis induced
by MDA-MB-435 parental cells [24], we examined whether
integrin avb3 was associated with ERa-induced inhibition
of bone metastasis by MDA-MB-435-F-L cells. As shown
in Figure 3A, the protein levels of both integrin av and b3
Table 1. Inhibition of Bone Metastasis in Breast Cancer Cells By the Ectopic
Expression of ERa.
(A) Incidence of cancer cell metastasis to the bone marrow,
as detected by whole-mouse EGFP imaging in MDA-MB-435-F-L
cell – inoculated mice
Specimen Control ER.Cl.3 ER.Cl.6
Legs 6/8 0/6* 0/6*
Mandible 3/4 0/3* 0/3*
Spine 3/4 1/3 0/3
Arms 1/8 0/6 0/6
(B) Incidence of osteolytic bone metastasis, as detected by X-ray
radiography in MDA-MB-231 cell – inoculated mice
Specimen Control ER.Cl.11 ER.Cl.15
Legs 8/10 1/10* 1/10*
Arms 4/10 0/10* 1/10*
*Statistically significant (P = .05; Fisher’s exact probability test) compared to
their respective controls, as determined on the VassarStats Web site (http://
faculty.vassar.edu/lowry/VassarStats.html).
Figure 2. Inhibition of bone invasion and osteolytic metastasis by the ectopic
expression of ERa. Control and ERa cells of MDA-MB-231 and MDA-MB-435-
F-L were inoculated through the left cardiac ventricle of female nude mice at
0.1  106 cells/mouse. Osteolytic bone metastasis induced by MDA-MB-231
cells was detected with X-ray radiographs, as indicated with an arrow in (A).
At the termination of the experiment, the femora and tibiae were fixed in
buffered formalin and decalcified. Paraffin-embedded sections were stained
with hematoxylin, eosin, orange G, and phloxine. Representative pictures of
the stained tibial sections of MDA-MB-231 (B) and MDA-MB-435-F-L (C)
cell – inoculated mice are presented.
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subunits were markedly lower in the two ERa clones of MDA-
MB-435-F-L cells than in control cells, suggesting that the
inhibition of integrin avb3 may be one of the mechanisms by
which ERa inhibits bone metastasis. The expression of in-
tegrin av in MDA-MB-231 cells was undetectable with West-
ern blot analysis. Previous studies have shown that ectopic
expression of integrin avb3 stimulated the bone-metastatic
potential of MDA-MB-231 cells [26]. Thus, ERa-induced in-
hibition of the bone-metastatic potential of MDA-MB-231 is
not likely due to the inhibition of integrin avb3 expression.
Another cell surface receptor that has been shown to pro-
mote the homing of cancer cells to the bone is RANK. It has
been shown that cytokine RANK ligand, which is expressed
by stromal cells and osteoblasts, can trigger the migration
and bone metastasis of human epithelial cancer cells ex-
pressing RANK [29]. We found that both MDA-MB-231 and
MDA-MB-435-F-L cells express RANK protein, which was
noticeably reduced in their respective ERa clones (Figure 3,
A and B). Thus, reduction of RANK expression in ERa-
expressing cells may be another mechanism for the impair-
ment of bone-metastatic potential by ERa. Future studies will
be necessary for the elucidation of whether the dramatic
blockade of bone-metastatic potential in the two breast
cancer cell lines by the expression of ERa is mainly due to
the attenuation of the integrin avb3 and RANK pathways.
In summary, our study demonstrates that restoration of
functional ERa expression in ERa-negative human breast
cancer cells can block their aggressive bone-metastatic
potential, supporting the notion that ERa confers a less
aggressive phenotype of breast cancer. Although the mech-
anism by which ERa suppresses metastatic potential is
currently not clear, our data suggest a potential involvement
of the integrinavb3 and/or the RANKpathway inmediating the
metastasis-suppressive action of ERa signaling.
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